1. Cytoskeleton
  2. Integrin
  3. LXW7 TFA

LXW7 TFA 

Cat. No.: HY-P0178A Purity: 99.17%
Handling Instructions

LXW7 TFA, a cyclic peptide containing Arg-Gly-Asp (RGD), is an integrin αvβ3 inhibitor. LXW7 has a high binding affinity to αvβ3 integrin with an IC50 of 0.68 μM. LXW7 TFA increases phosphorylation of VEGFR-2 and activation of ERK1/2. Anti-inflammatory effect.

For research use only. We do not sell to patients.

Custom Peptide Synthesis

LXW7 TFA Chemical Structure

LXW7 TFA Chemical Structure

Size Price Stock Quantity
10 mM * 1 mL in Water USD 3908 In-stock
Estimated Time of Arrival: December 31
1 mg USD 1350 In-stock
Estimated Time of Arrival: December 31
5 mg USD 2800 In-stock
Estimated Time of Arrival: December 31
10 mg USD 3800 In-stock
Estimated Time of Arrival: December 31
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of LXW7 TFA:

Top Publications Citing Use of Products
  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

LXW7 TFA, a cyclic peptide containing Arg-Gly-Asp (RGD), is an integrin αvβ3 inhibitor. LXW7 has a high binding affinity to αvβ3 integrin with an IC50 of 0.68 μM. LXW7 TFA increases phosphorylation of VEGFR-2 and activation of ERK1/2. Anti-inflammatory effect[1][2][3].

IC50 & Target

IC50: 0.68 μM (αvβ3 integrin)[1]

In Vitro

LXW7 specially binds to αvβ3 integrin (Kd=76±10 nM). LXW7 binds strongly to αvβ3-K562 cells, weakly to αvβ5-K562 cells and αIIbβ3-K562 cells, and no binding to K562 cells. LXW7 has great potential as a highly efficient peptide ligand for targeted imaging and drug delivery[1].
LXW7 acts as a potent and specific endothelial progenitor cells (EPCs) and endothelial cells (ECs) targeting ligand[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

LXW7 (100 μg/kg; intravenous injection) significantly lowers infarct volumes and brain water content (BWC) LXW7-treated rats. The LXW7 treatment lowers the expression of pro-inflammatory cytokines[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male Sprague-Dawley rats (250-280 g) subjected to middle cerebral artery occlusion (MCAO)[3]
Dosage: 100 μg/kg
Administration: Intravenous injection
Result: Infarct volumes and BWC were significantly lower compared to those in the MCAO+PBS (control) group.
Molecular Weight

934.92

Formula

C₃₁H₄₉F₃N₁₂O₁₄S₂

Sequence

Cys-Gly-Arg-Gly-Asp-Asp-Val-Cys-NH2 (Disulfide bridge:Cys1-Cys8)

Sequence Shortening

CGRGDDVC-NH2 (Disulfide bridge:Cys1-Cys8)

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Sealed storage, away from moisture

Powder -80°C 2 years
-20°C 1 year

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Solvent & Solubility
In Vitro: 

H2O

Peptide Solubility and Storage Guidelines:

1.  Calculate the length of the peptide.

2.  Calculate the overall charge of the entire peptide according to the following table:

  Contents Assign value
Acidic amino acid Asp (D), Glu (E), and the C-terminal -COOH. -1
Basic amino acid Arg (R), Lys (K), His (H), and the N-terminal -NH2 +1
Neutral amino acid Gly (G), Ala (A), Leu (L), Ile (I), Val (V), Cys (C), Met (M), Thr (T), Ser (S), Phe (F), Tyr (Y), Trp (W), Pro (P), Asn (N), Gln (Q) 0

3.  Recommended solution:

Overall charge of peptide Details
Negative (<0) 1.  Try to dissolve the peptide in water first.
2.  If water fails, add NH4OH (<50 μL).
3.  If the peptide still does not dissolve, add DMSO (50-100 μL) to solubilize the peptide.
Positive (>0) 1.  Try to dissolve the peptide in water first.
2.  If water fails, try dissolving the peptide in a 10%-30% acetic acid solution.
3.  If the peptide still does not dissolve, try dissolving the peptide in a small amount of DMSO.
Zero (=0) 1.  Try to dissolve the peptide in organic solvent (acetonitrile, methanol, etc.) first.
2.  For very hydrophobic peptides, try dissolving the peptide in a small amount of DMSO, and then dilute the solution with water to the desired concentration.
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2

Keywords:

LXW7LXW 7LXW-7Integrinαvβ3integrinVEGFR-2ERK1/2Anti-inflammatoryInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

 

Salutation

Applicant Name *

 

Email address *

Phone number *

 

Organization name *

Department *

 

Requested quantity *

Country or Region *

     

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
LXW7 TFA
Cat. No.:
HY-P0178A
Quantity:
MCE Japan Authorized Agent: